GlycoMimetics (NASDAQ:GLYC – Get Rating) had its price target cut by investment analysts at HC Wainwright from $14.00 to $13.00 in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The firm currently has a “buy” rating on the biotechnology company’s stock.
Separately, StockNews.com initiated coverage on shares of GlycoMimetics in a research note on Thursday, July 28th. They set a “hold” rating for the company.
GlycoMimetics Price Performance
Shares of GLYC opened at $0.90 on Thursday. The firm has a 50-day moving average of $0.65 and a 200-day moving average of $0.87. GlycoMimetics has a one year low of $0.51 and a one year high of $2.50.
Institutional Trading of GlycoMimetics
GlycoMimetics Company Profile
GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML.
- Get a free copy of the StockNews.com research report on GlycoMimetics (GLYC)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.